Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER

• Published in: Respiratory research 2020-10, Vol.21 (1), p.1-285, Article 285
• Main Authors: Singh, Dave, Virchow, Johann Christian, Canonica, Giorgio Walter, Vele, Andrea, Kots, Maxim, Georges, George, Papi, Alberto
• Format: Article
• Language: English
• Subjects: Acetylcholine receptors (muscarinic); Age; Asthma; Beclomethasone; Clinical trials; Comparative analysis; Development and progression; Drug therapy; Formoterol; Glycopyrrolate; Inhaled corticosteroids; Inhalers; Leukocytes (eosinophilic); Long-acting muscarinic antagonists; Long-acting β2-agonists; Lungs; Patients; Pharmacotherapy; Respiratory function; Subgroup analyses; Trimaran ships; Values
• ISSN: 1465-993X; 1465-9921; 1465-993X; 1465-9921
• DOI: 10.1186/s12931-020-01558-y

Background A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to the addition of the long-acting muscarinic antagonist component within inhaled triple therapy was impacted by a range of clinical characteristics. Methods These were pre-specified and post-hoc sub-group analyses of TRIMARAN and TRIGGER, which were double-blind, 52-week studies comparing medium-strength (100/6/10 [micro]g; TRIMARAN) and high-strength (200/6/10 [micro]g; TRIGGER) BDP/FF/G with the respective BDP/FF strengths in adults with uncontrolled asthma and a history of [greater than or equai to] 1 exacerbation. Co-primary endpoints were pre-dose forced expiratory volume in 1 s (FEV.sub.1) at Week 26 and the rate of moderate-to-severe exacerbations over 52 weeks. Key secondary endpoints: peak FEV.sub.1 at Week 26 and average morning peak expiratory flow over the first 26 weeks in each study, and severe exacerbation rate over 52 weeks (pooled data). Results Baseline clinical characteristics (pre-specified analyses) had no consistent effect on the lung function improvements with BDP/FF/G. For the exacerbation endpoints, sub-groups with higher reversibility gained greatest relative benefit from BDP/FF/G versus BDP/FF. In post-hoc analyses with patients sub-grouped by screening blood eosinophil values, in TRIMARAN the greatest relative effect of BDP/FF/G versus BDP/FF on the lung function endpoints was in the [less than or equai to] 300 cells/[micro]L group; in TRIGGER, eosinophil levels did not markedly influence the relative efficacy of BDP/FF/G versus BDP/FF. Eosinophil levels did not influence relative efficacy on moderate-to-severe or severe exacerbations. Conclusion Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, Keywords: Asthma, Pharmacotherapy, Long-acting [beta].sub.2-agonists, Long-acting muscarinic antagonists, Inhaled corticosteroids, Subgroup analyses, Eosinophils